In HCC, activation of the Sterol regulatory element-binding protein 2 (SREBP2)–3-Hydroxy-3-methylglutaryl-CoA reductase (HMGCR) axis can enhance the cholesterol biosynthesis pathway, leading to drug resistance. This evidence concerns the gene SREBF2 and hepatocellular carcinoma.